Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Non-Current Liabilities (2020 - 2022)

Ovid Therapeutics' Total Non-Current Liabilities history spans 3 years, with the latest figure at $26.1 million for Q1 2022.

  • For Q1 2022, Total Non-Current Liabilities rose 59.67% year-over-year to $26.1 million; the TTM value through Mar 2022 reached $26.1 million, up 59.67%, while the annual FY2021 figure was $14.8 million, 54.18% down from the prior year.
  • Total Non-Current Liabilities reached $26.1 million in Q1 2022 per OVID's latest filing, up from $14.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $32.3 million in Q4 2020 to a low of $10.1 million in Q3 2021.
  • Average Total Non-Current Liabilities over 3 years is $18.2 million, with a median of $14.9 million recorded in 2020.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 64.0% in 2021, then skyrocketed 59.67% in 2022.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $32.3 million in 2020, then plummeted by 54.18% to $14.8 million in 2021, then soared by 76.37% to $26.1 million in 2022.
  • Per Business Quant, the three most recent readings for OVID's Total Non-Current Liabilities are $26.1 million (Q1 2022), $14.8 million (Q4 2021), and $10.1 million (Q3 2021).